How does lebrikizumab perform across different racial and ethnic subgroups?

The article explores the efficacy of lebrikizumab, an interleukin-13 inhibitor, in treating moderate-to-severe atopic dermatitis across different racial and ethnic subgroups. The study presented findings from the 16-week induction periods of the phase 3 ADvocate1 and ADvocate2 trials, indicating significant effectiveness in diverse populations, although additional studies are needed for verification.